Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 15 min ago
PreprintAll rights reservedbioRxiv

A Visually Interpretable Histopathology-Based Immune Model Predicts T-effector Biology and Response to Immune checkpoint inhibition in Clear Cell Renal Cell Carcinoma Clinical Trial and Contemporary Real-World Datasets

  • A. Perny
  • V. Jarmale
  • J. Jasti
  • H. Zhong
  • A. L. Christie
  • J. Miyata
  • A. W. Nielsen
  • P. Kontoyiannis
  • D. Rakheja
  • Z. Modrusan
  • M. Huseni
  • W. Kadel
3 more authors
  • J. Brugarolas
  • P. Kapur
  • S. Rajaram1
  1. 1UT Sothwestern Medical Center
Read full textPDFDOICite

Related

  1. Case Report: Durable complete response to dual immune checkpoint blockade and EGFR inhibition in microsatellite-stable metastatic duodenal adenocarcinoma
    Chia-Ying Wu, Kuan-Chang Lai, Pei-Ying Hsieh +1
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref
  2. Computational modeling of breast cancer metastases predicts response to dual checkpoint inhibition and reveals spatially-informed treatments
    T. King, E. Gonzalez, E. T. Roussos Torres +1
    bioRxivPreprintCC BY-NC-NDFull textSystems & synthetic biologybioRxiv
  3. The SChISM study: Circulating cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors
    Linh Nguyen Phuong, Frederic Fina, Laurent Greillier +10
    HALPreprintCC BY-NC-SA 4.0Full textMolecular biology & gene regulationBioinformatics & computational biologyHAL
  4. Gαi3 acts as a metabolic checkpoint orchestrating TAMs immunosuppression and lipid metabolism in glucose-deprived hepatocellular carcinoma
    Meixi Lu, Yaoyao Li, Siyu Du +11
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BY-NC 4.0Full textImmunologyDOAJPMC
  5. First-line immune checkpoint inhibitors combined with targeted therapy for advanced renal cell carcinoma: a network meta-analysis and cost-effectiveness analysis
    Yize Jia, Shan Zhao, Xiaohui Wang +1
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@misc{perny2026visually,
  title = {{A Visually Interpretable Histopathology-Based Immune Model Predicts T-effector Biology and Response to Immune checkpoint inhibition in Clear Cell Renal Cell Carcinoma Clinical Trial and Contemporary Real-World Datasets}},
  author = {A. Perny and V. Jarmale and J. Jasti and H. Zhong and A. L. Christie and J. Miyata and A. W. Nielsen and P. Kontoyiannis and D. Rakheja and Z. Modrusan and M. Huseni and W. Kadel and J. Brugarolas and P. Kapur and S. Rajaram},
  howpublished = {bioRxiv},
  year = {2026},
  month = jun,
  doi = {10.64898/2026.06.21.733614},
  url = {https://www.biorxiv.org/content/10.64898/2026.06.21.733614v2},
}
RIS
TY  - UNPB
TI  - A Visually Interpretable Histopathology-Based Immune Model Predicts T-effector Biology and Response to Immune checkpoint inhibition in Clear Cell Renal Cell Carcinoma Clinical Trial and Contemporary Real-World Datasets
AU  - A. Perny
AU  - V. Jarmale
AU  - J. Jasti
AU  - H. Zhong
AU  - A. L. Christie
AU  - J. Miyata
AU  - A. W. Nielsen
AU  - P. Kontoyiannis
AU  - D. Rakheja
AU  - Z. Modrusan
AU  - M. Huseni
AU  - W. Kadel
AU  - J. Brugarolas
AU  - P. Kapur
AU  - S. Rajaram
PY  - 2026
DA  - 2026/06/21
PB  - bioRxiv
DO  - 10.64898/2026.06.21.733614
UR  - https://www.biorxiv.org/content/10.64898/2026.06.21.733614v2
ER  -